Overview
Objective of this study is to determine the clinical benefits of trimetazidine in improvement of MAFLD
Description
the study will evaluate the possible benefits of trimetazidine when added to pateints with metabolic associated fatty liver disease
Eligibility
Inclusion Criteria:Patients presented to hepatology clinic .
- Patients are diagnosed by ultrasonography and laboratory tests for liver and lipids.
- Patients with comorbidites like hypertension,diabetes,dyslipidemia, insuline resistance , increase in west circumstanses
Exclusion Criteria:Exclusion criteria included the presence of liver disease due to any of
the following:
- viral hepatitis (HBV, HCV)
- acute systemic disease
- cystic fibrosis, coeliac disease
- alcoholism pateints
- autoimmune hepatitis, drug toxicity and drugs known to induce steatosis (e.g.
valproate, amiodarone orprednisone)
- the use of nonsteroidal anti-inflammatory drugs,antibiotics,sglt2,dpp4,statins,glp1
- Patient with age below 18 or above 60